Evidence map›Paper›PMID 38024426›Full record

ReviewAsian journal of urology2023

A systematic review of robot-assisted partial nephrectomy outcomes for advanced indications: Large tumors (cT2-T3), solitary kidney, completely endophytic, hilar, recurrent, and multiple renal tumors.

Savio Domenico Pandolfo, Clara Cerrato, Zhenjie Wu, Antonio Franco, Francesco Del Giudice, Alessandro Sciarra, Paolo Verze, Giuseppe Lucarelli, Ciro Imbimbo, Sisto Perdonà and 4 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 4 countries.

Savio Domenico PandolfoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Clara CerratoDepartment of Urology, University of Verona, Verona, Italy.
Zhenjie WuDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Antonio FrancoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Francesco Del GiudiceDepartment of Maternal-Infant and Urologic Sciences, La Sapienza University, Policlinico Umberto I Hospital, Rome, Italy.
Alessandro SciarraDepartment of Maternal-Infant and Urologic Sciences, La Sapienza University, Policlinico Umberto I Hospital, Rome, Italy.
Paolo VerzeDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, Fisciano, Italy.
Giuseppe LucarelliDepartment of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
Ciro ImbimboDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, "Federico II" University, Naples, Italy.
Sisto PerdonàDepartment Uro-Gynecology, IRCCS G. Pascale Foundation, Naples, Italy.
Edward E CherulloDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Francesco PorpigliaDepartment of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
Ithaar H DerweeshDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Riccardo AutorinoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Rush University Medical Center · USFederico II University Hospital · ITPoliclinico Umberto I · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITSecond Military Medical University · CNUniversity of Bari Aldo Moro · ITUniversity of California, San Diego · USUniversity of Salerno · ITUniversity of Turin · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Robot-assisted partial nephrectomy (RAPN) has become widely used for treatment of renal cell carcinoma and it is expanding in the field of complex renal masses. The aim of this systematic review was to analyze outcomes of RAPN for completely endophytic renal masses, large tumors (cT2-T3), renal cell carcinoma in solitary kidney, recurrent tumors, completely endophytic and hilar masses, and simultaneous and multiple tumors. Methods: A comprehensive search in the PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials databases was performed in December 2022 for English language papers. The primary endpoint was to evaluate the role of RAPN in the setting of each category of complex renal masses considered. The secondary endpoint was to evaluate the surgical and functional outcomes. Results: After screening 1250 records, 43 full-text manuscripts were selected, comprising over 8500 patients. Twelve and thirteen studies reported data for endophytic and hilar renal masses, respectively. Five and three studies reported outcomes for cT2-T3 and solitary kidney patients, respectively. Four studies focused on redo-RAPN for recurrent tumors. Two studies investigated simultaneous bilateral renal masses and five reports focused on multiple tumor excision in ipsilateral kidney. Conclusion: Over the past decade, evidence supporting the use of RAPN for the most challenging nephron-sparing surgery indications has continuously grown. Although limitations remain including study design and lack of detailed long-term functional and oncological outcomes, the adoption of RAPN for the included advanced indications is associated with favorable surgical outcomes with good preservation of renal function without compromising the oncological result. Certainly, a higher likelihood of complication might be expected when facing extremely challenging cases. However, none of these indications should be considered

Indexed as

Complex renal massEndophytic and hilar massLarger tumors (cT2-T3)Recurrent tumorRobot-assisted partial nephrectomySimultaneous and multiple tumorSolitary kidney

Identifiers

PMID38024426
PMCPMC10659988
OpenAlexW4385455360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.